Australia’s Cannabis Platforms Face a Test of Who Controls the Prescription

Dr Joel Wren had practical reasons to recommend a pharmacy: it knew cannabis medicines, charged the expected price and could get an order moving. But the patient could take the prescription elsewhere. Wren, then president of Cannabis Clinicians Australia and a doctor working with Polln, described that choice in a March 2024 interview with The Medical Republic. (S1)

An online clinic can bring the consultation, prescription and pharmacy order into one service. Polln’s own platform offers that kind of coordination. For the patient, there are fewer steps to manage. For a connected business, there are more opportunities to keep the transaction within the group. The clinical decision has to retain its independence inside that convenient sequence. (S2, S9)

Australia’s Therapeutic Goods Administration has now made the structure of unapproved-medicine supply a priority for the coming year. Its business plan, published September 2, 2026, commits to examining reform options for unapproved medicinal cannabis. Separately, it identifies closed-loop supply chains among the areas where it wants appropriate frameworks for therapeutic goods outside the Australian Register of Therapeutic Goods. (S3)

The plan puts the route from prescriber to patient alongside the product itself. The TGA says its cannabis review will focus on patient safety, greater sponsor responsibility and regulation proportionate to risk. Connected services now face a question about their design: whether the arrangement helps a patient obtain appropriate care or quietly makes a commercial decision before the consultation begins. (S3)

Business of Cannabis highlighted the connection in its September 4 report on the plan. The outlet interpreted the closed-loop language as relevant to vertically connected cannabis businesses. That is a reasonable reading of the direction of travel, rather than an announced cannabis-specific restriction. The plan contains no completed package of clinic-ownership reforms or commencement date for one. (S4, S3)

Much of the existing system runs through exceptional-access pathways. The TGA explains that most medicinal cannabis products supplied in Australia are unapproved: they have not undergone its individual assessment for safety, quality and effectiveness. The Special Access Scheme and Authorised Prescriber pathway allow access under specified arrangements. Permission to supply through those routes is different from registration of the medicine itself. (S8)

That distinction is easy to lose in an efficient online experience. A patient sees an appointment, a clinician and an order. The administrative category sits in the background. In its April 2026 summary of consultation responses, the TGA said many consumers did not understand the implications of unapproved status. It identified education for patients and practitioners as an immediate area of work. (S5)

The regulator received 786 submissions before the consultation closed on October 7, 2025. Its summary described support for reform alongside concern about disrupting access. Respondents raised product quality, prescribing practices, labelling and the evidence available to guide treatment. The task is therefore broader than deciding whether online care should exist. It includes what patients are told and whether the system can preserve sound decisions as demand grows. (S5)

Justin Untersteiner, CEO of the Australian Health Practitioner Regulation Agency, put the conflict plainly in July 2025. Ahpra warned about businesses built around prescribing a single medicine or drug class, including questionnaires that could steer patients toward answers supporting a prescription. It also reported eight practitioners issuing more than 10,000 prescriptions each in six months, with one apparently exceeding 17,000. Those figures were warning signs for investigation, rather than findings against every high-volume clinic. (S6)

Dr Susan O’Dwyer, chair of the Medical Board of Australia, framed the professional responsibility in terms of clinical need. Her point was that a request for a medicine cannot substitute for an assessment. For a platform, that introduces a necessary source of friction: some appointments should end with a different treatment or no cannabis prescription. A service has to remain useful even when its clinician declines the sale. (S6)

“Patient demand is no indicator of clinical need.”

— Dr Susan O’Dwyer, Chair, Medical Board of Australia, July 9, 2025 (S6)

Ahpra’s prescribing guidance makes a particular demand on connected businesses: declaring a financial conflict on a website is insufficient. Practitioners must explain the conflict to patients and be able to show that it does not affect care. Assessment, records and coordination with other treating practitioners also remain part of the job. The guidance also requires practitioners to assess whether telehealth remains appropriate and arrange an in-person consultation when necessary. The booking page can be simple. The decision behind it requires more work. (S9)

The commercial questions are specific.

What products can the prescriber consider? How are financial interests explained? Can the patient use another pharmacy? A company’s answers should be visible in the way its service operates. A claim of independence means little if the available choices lead every consultation toward the same supplier.

The point of dispensing adds another professional decision. Dr Cameron Phillips, chair of the Pharmacy Board of Australia, said in September 2025 that the rapid increase in cannabis prescriptions made a reminder of pharmacists’ obligations timely. The board’s guidance calls for appropriate assessment before supply and communication with the prescriber where concerns arise. A prescription arriving electronically does not remove that responsibility. (S7)

The Pharmacy Board also draws attention to the risk of allowing financial arrangements to affect care. That matters when a platform presents the path from consultation to checkout as a single smooth transaction. A pharmacist’s question can slow the transaction and still improve the service. Independence is easiest to see at the point where someone has the authority to interrupt an order. (S7)

A familiar pharmacy can make care easier. Wren described variable experience among pharmacists, differences in prices and delays in ordering. He said Polln’s preferred pharmacy helped patients through that process, while leaving them free to choose another. Close coordination had a practical purpose in his account. (S1)

Polln’s current public FAQ shows how much service can be gathered into one platform. It describes consultations, prescription management, pharmacy requests, delivery and ongoing nurse support. It also says medication is dispensed at recommended retail prices and that Polln adds no mark-ups to pharmacy pricing. These are the company’s service claims, rather than an independent assessment, but they explain the appeal of handling an unfamiliar treatment process through one provider. (S2)

A patient comparing services therefore has more to consider than the consultation fee. Time, delivery, follow-up and the ease of resolving an unavailable product can all affect the experience. Removing coordination without preserving a workable alternative could leave patients doing more of that work themselves. The reform challenge is to keep those practical benefits while ensuring that convenience does not decide what gets prescribed. (S1, S2, S5)

Industry groups have made continuity of access a central demand. In their October 7, 2025 joint submission, the Australian Medicinal Cannabis Association and Medicinal Cannabis Industry Australia argued that patients should retain access to current products during the review. The submission identified Dr Teresa Nicoletti as AMCA’s chair and Kristin Viccars as MCIA’s chair. It advocated changes tied to evidence and risk, with affordability among the considerations. (S10)

The submission did not dismiss the need for stronger oversight. It supported improvements in professional education and prescribing standards, while opposing broad restrictions the groups considered disproportionate. That position has a commercial interest behind it: the organisations represent industry participants as well as other members. It also puts a real policy cost on the table. A reform can address poor practice and still impose burdens on patients already receiving care. (S10)

The TGA’s own consultation summary records similar concern about the effect of changes on access. This gives the debate a more useful shape than a simple divide between industry and regulators. Both describe a need for safer care. The disagreement is over which controls would improve it, how strong the evidence must be and how much disruption is justified along the way. (S5, S10)

The technology is part of that argument because it can serve either purpose. A shared system can make records and follow-up easier to manage. It can also make a narrow route to one supplier feel like the only available route. The screen may look equally convenient in both cases. The distinction depends on the choices available to clinicians and patients, and on whether the business respects them in practice. (S2, S9)

The next meaningful development will be a concrete reform proposal: its scope, the businesses and practitioners it covers, and the arrangements for patients already in care. The business plan establishes the TGA’s direction but leaves that design work open. In the meantime, the professional standards provide a way to judge present conduct without waiting for an entirely new framework. (S3, S9)

A platform earns trust when it remains helpful after someone chooses a different route. Wren’s account provides a practical example: explain the preferred pharmacy, make it work well, and allow the prescription to leave. That freedom belongs in the service as much as the booking button. (S1)

Keep Reading

Tech & E-Commerce

'Brand Name or Equal to Brightfield': FDA Seeks AI Reading of Cannabis Posts on TikTok and Reddit

An August request for quotes seeks a contractor to mine TikTok, Instagram and Reddit conversations, survey dispensary shoppers by symptom and dose, and map the CBD market through September 2027. It names one Chicago research firm as the benchmark, and it traces straight back to December's research executive order.

By Cannabis Inc, Editorial Staff·7 min read

Tech & E-Commerce

Weedmaps Was Worth $1.5 Billion. It Just Quit Nasdaq Worth $45 Million.

Justin Hartfield's gray-market dispensary directory grew into the SPAC era's cannabis darling, then the 'cannabis winter' and a regulatory reckoning gutted it. On April 24, a smaller, profitable WM Technology delisted to the OTC markets, with its CEO calling the retreat a path to victory.

By Cannabis Inc, Editorial Staff·8 min read